NeuroSense Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
NeuroSense Therapeutics Depreciation & Amortization Growth & History (NRSN)
NeuroSense Therapeutics's depreciation and amortization was $16,000 for fiscal 2025.
View full NeuroSense Therapeutics company overviewNeuroSense Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $16,000 | −$6,000 | −27.27% |
| 2024 | 2024-12-31 | $22,000 | $1,000 | +4.76% |
| 2023 | 2023-12-31 | $21,000 | $9,000 | +75.00% |
| 2022 | 2022-12-31 | $12,000 | $9,000 | +300.00% |
| 2021 | 2021-12-31 | $3,000 | $0 | 0.00% |
| 2020 | 2020-12-31 | $3,000 | — | — |
NeuroSense Therapeutics depreciation and amortization trends
Over the last five fiscal years, NeuroSense Therapeutics's depreciation and amortization increased from $3,000 to $16,000, a change of $13,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NeuroSense Therapeutics source filings ↗